Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Biotech Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Biotech Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: biotech, biotechnology, biopharma, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Biotech.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to biotech; however, a few may just somewhat depend and/or be indirectly related to biotech. As always complete your own due diligence.


Biotech Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































2.378B


































136.174B


























































































































































N/A


Recent Biotech Posts (Pulses)




01/-0/2018: $HEB (Hemispherx Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.22. -- Go to this Pulse Post



01/-0/2018: $HEB (Hemispherx Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $BNTC (Benitec Biopharma LTD) is significantly more volatile than the overall market with a Beta of 3.98. -- Go to this Pulse Post



01/-0/2018: $ABUS (Arbutus Biopharma Corporation) has significant institutional ownership of at least 20% with institutional ownership of 98.36%. -- Go to this Pulse Post



01/-0/2018: $BNTC (Benitec Biopharma LTD) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $SBBP Strongbridge Biopharma announced that the USPTO has entered a Notice of Allowance for U.S. Patent Application 15/088,539 covering the use of RECORLEV (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. -- Go to this Pulse Post



01/-0/2018: If $82 billion $CELG buys $5 billion $JUNO it would bring money flowing back into biotech sector as a whole. $LABU could catch fire. -- Go to this Pulse Post



01/-0/2018: $AMRS Amyris received two grants valued in aggregate at approx. $25M to accelerate innovation and enable the company to further extend its leadership position in the industrial biotechnology sector. -- Go to this Pulse Post



01/-0/2018: $BNTC Benitec Biopharma announced that the FDA has granted Orphan Drug Designation to BB-301 for the treatment of oculopharyngeal muscular dystrophy (OPMD. -- Go to this Pulse Post



01/-0/2018: $RDHL RedHill Biopharma announced top-line final results from the Phase II clinical study with BEKINDA 12 mg (RHB-102) for the treatment of diarrhea-predominant irritable bowel syndrome. -- Go to this Pulse Post



01/-0/2018: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 81.30%. -- Go to this Pulse Post



01/-0/2018: $NEXS (Nexus Biopharma, Inc.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $KERX (Keryx Biopharmaceuticals Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $49.62M. -- Go to this Pulse Post



01/-0/2018: $KERX (Keryx Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(86.5M). -- Go to this Pulse Post



01/-0/2018: $KERX (Keryx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.90. -- Go to this Pulse Post



01/-0/2018: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 67.94%. -- Go to this Pulse Post



01/-0/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.96. -- Go to this Pulse Post



01/-0/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $GALE (Galena Biopharma, Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $100.23M. -- Go to this Pulse Post



01/-0/2018: $GALE (Galena Biopharma, Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $57.87M. -- Go to this Pulse Post



01/-0/2018: $HEB (Hemispherx Biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(240,477). -- Go to this Pulse Post



01/-0/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $118,379. -- Go to this Pulse Post



01/-0/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 1.72. -- Go to this Pulse Post



01/-0/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 52.66%. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.50. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) has significant insider ownership of at least 20% with insider ownership of 69.98%. -- Go to this Pulse Post



01/-0/2018: $CUE (Cue Biopharma Inc.) did not produce a profit last quarter with Quarterly Net Income of $(5.03M). -- Go to this Pulse Post



01/-0/2018: $CUE (Cue Biopharma Inc.) has significant insider ownership of at least 20% with insider ownership of 84.35%. -- Go to this Pulse Post



01/-0/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: Two companies recently holding their Initial Public Offering: $NEBUU (Nebula Acquisiti), $CUE (Cue Biopharma, I). -- Go to this Pulse Post



01/-0/2018: $SBFM (Sunshine Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 42.6%. -- Go to this Pulse Post



01/-0/2018: $TBPH (Theravance Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.13. -- Go to this Pulse Post



01/-0/2018: $TBPH (Theravance Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 81.08%. -- Go to this Pulse Post



01/-0/2018: $BNTCW (Benitec Biopharma Limited) is down more than 20%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $NEXS (Nexus Biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $BGNE BeiGene and Boehringer Ingelheim Biopharmaceuticals announce commercial supply agreement for Anti-PD-1 antibody tislelizumab. -- Go to this Pulse Post



01/-0/2018: $ALDR (Alder Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $ABIO (ARCA biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 1.40. -- Go to this Pulse Post



01/-0/2018: $ABIO (ARCA biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 67.99%. -- Go to this Pulse Post



01/-0/2018: $KERX (Keryx Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 411.5%. -- Go to this Pulse Post



01/-0/2018: $NEXS (Nexus Biopharma, Inc.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: Two companies recently holding their Initial Public Offering: $CUE (Cue Biopharma, I), $JAN30, 2018 (Recently Priced ). -- Go to this Pulse Post



01/-0/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.86. -- Go to this Pulse Post



01/-0/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 276.25%. -- Go to this Pulse Post



01/-0/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.92. -- Go to this Pulse Post



01/-0/2018: $SNNA (Sienna Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.08. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.34. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) has significant insider ownership of at least 20% with insider ownership of 212.31%. -- Go to this Pulse Post



01/-0/2018: $INBP (Integrated Biopharma Inc.) has significant institutional ownership of at least 20% with institutional ownership of 69.98%. -- Go to this Pulse Post



01/-0/2018: $ALDR (Alder Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.22. -- Go to this Pulse Post



01/-0/2018: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 96.03%. -- Go to this Pulse Post



01/-0/2018: $NEXS (Nexus Biopharma, Inc.) is down more than 20%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $SBMFF (Sino Biopharmaceutical Ltd.) could become a potential short squeeze opportunity with significant short interest of 18.51%. -- Go to this Pulse Post



01/-0/2018: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.98. -- Go to this Pulse Post



01/-0/2018: $RDHL (RedHill Biopharma Ltd.) could become a potential short squeeze opportunity with significant short interest of 19.39%. -- Go to this Pulse Post



01/-0/2018: $ITB Homebuidlers (ITB -1%) lag late in the session while retail (XRT -1%) and biotech (XBI -0.9%) are well off session lows vs. SPY +0.5%. -- Go to this Pulse Post



01/-0/2018: $MSDI Monster Digital and Innovate Biopharmaceuticals to extend the outside closing date of their previously announced reverse merger; MSDI also requested a further extension to regain compliance w/ the Nasdaq. -- Go to this Pulse Post



01/-0/2018: $EBS Emergent BioSolutions initiated a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients. -- Go to this Pulse Post



01/-0/2018: $NEXS (Nexus Biopharma, Inc.) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $ABIO (ARCA biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 48.73%. -- Go to this Pulse Post



01/-0/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $CUE (Cue Biopharma Inc.) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $NEXS (Nexus Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



01/-0/2018: $GALE Galena Biopharma completed merger with SELLAS Life Sciences Group. -- Go to this Pulse Post



01/-0/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $CUE (Cue Biopharma Inc.) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



01/-0/2018: $GALE Galena Biopharma completed merger with SELLAS Life Sciences Group. -- Go to this Pulse Post



01/-0/2018: $ABIO (ARCA biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 46.06%. -- Go to this Pulse Post



01/-0/2018: $ABIO (ARCA biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 41.05%. -- Go to this Pulse Post



01/-0/2018: $HEB (Hemispherx Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 89.48%. -- Go to this Pulse Post



01/-0/2018: $GALE Galena Biopharma to effect the reverse stock split of the Galena common stock at a ratio of 1for-30; reverse stock split is expected to become effective at 4:15 p.m. ET today, December 29, 2017. -- Go to this Pulse Post



01/-0/2018: $TBPH (Theravance Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 78.29%. -- Go to this Pulse Post



01/-0/2018: $TBPH (Theravance Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 27.41%. -- Go to this Pulse Post



01/-0/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.79. -- Go to this Pulse Post



01/-0/2018: $NAVB (Navidea Biopharmaceuticals, Inc) has significant insider ownership of at least 20% with insider ownership of 95.76%. -- Go to this Pulse Post